chamomile gummy
Phase 3Small molecule
chamomile gummy is one of 45 small molecule programs targeting Anxiety. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
61 competitors in Anxiety
#DrugCompanyPhaseTrials
1Versed
CConrado Roberto Hoffmann Filho
Approved
Lexapro
AbbVieApproved
Ritalin
NovartisApproved
Cymbalta
Jazz PharmaceuticalsApproved
Neupro
UCBApproved
Buspar
Bristol-Myers SquibbApproved
Xanax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Namenda
AbbVieApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Anxiety1 trial
Chamomile Gummies and Pediatric Dental Anxiety
Not yet recruiting·—·Phase 2/3·NCT07138391·78 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for chamomile gummy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- AAin Shams University